Search | Clinical Trials Finder

Conditions: Acetaminophen, Drug Overdose, Acetaminophen Overdose, Acetaminophen Poisoning, Drug-induced Liver Injury, Liver Failure, Liver Toxicity
Interventions: Intravenous infusion of N-acetylcysteine, Intravenous infusion of Fomepizole (4-MP); Drug
Lead sponsor: Richard Dart, MD, PhD; Other
Eligibility: 10 Years to 99 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Lip and Oral Cavity Squamous Cell Carcinoma, Oral Cavity Verrucous Carcinoma, Precancerous Condition
Interventions: vandetanib, placebo, immunohistochemistry staining method, laboratory biomarker analysis, biopsy, pharmacological study; Drug · Other · Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Migraine Headache
Interventions: Propranolol or nadolol, Placebo control, Behavioral Migraine Management (BMM), Optimal Acute Therapy; Drug · Behavioral
Lead sponsor: Ohio University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 2
States / cities: Athens, Ohio • Westerville, Ohio

Conditions: Binge Eating, Depression
Interventions: Duloxetine, Placebo; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Arterial Disease of Legs, Below-the-knee Obstruction, PAD - Peripheral Arterial Disease
Interventions: MagicTouch PTA Sirolimus drug coated balloon, Placebo balloon angioplasty; Device
Lead sponsor: Concept Medical Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 29
States / cities: Scottsdale, Arizona • Los Angeles, California • Clearwater, Florida + 22 more

Conditions: Healthy Participants
Interventions: AZD4144- Part A, Placebo- Part A, AZD4144- Part B, Placebo- Part B, Rosuvastatin and Furosemide- Part C, Rosuvastatin, Furosemide, and AZD4144 Part C; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Tobacco Dependence
Interventions: varenicline, placebo; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 163 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Cystic Fibrosis Related Bone Disease
Interventions: Estradiol 2 mg, Placebo; Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Type 2 Diabetes (T2D)
Interventions: NNC0487-0111 subcutanous, Placebo (NNC0487-0111 subcutanous), NNC0487-0111 oral, Placebo (NNC0487-0111 oral); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 39
States / cities: Birmingham, Alabama • Los Angeles, California • Santa Ana, California + 30 more

Conditions: Infertility, Endometriosis
Interventions: Elagolix 200 MG, Placebo or SOC IVF; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 5
States / cities: Aurora, Colorado • New Haven, Connecticut • Chicago, Illinois + 2 more

Conditions: HIV Infections
Interventions: Nelfinavir mesylate; Drug
Lead sponsor: Agouron Pharmaceuticals; Industry
Eligibility: 13 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 4
States / cities: Birmingham, Alabama • Los Angeles, California • New Orleans, Louisiana + 1 more

Conditions: HIV Infections
Interventions: VH4011499 low dose Injection, VH4011499 high dose Injection, Placebo; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 168 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Las Vegas, Nevada • Austin, Texas

Conditions: Treatment Resistant Major Depressive Disorder
Interventions: AZD6765, Placebo to AZD6765; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Dysphagia
Interventions: Dexamethasone, Saline; Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Saphenous Vein Graft Atherosclerosis
Interventions: Alirocumab 150 MG/ML subcutaneous injection, Matching Placebo subcutaneous injection; Drug
Lead sponsor: Minneapolis Heart Institute Foundation; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 4
States / cities: San Francisco, California • Atlanta, Georgia • Minneapolis, Minnesota + 1 more

Conditions: Otolaryngeal Cancer
Interventions: Ketamine, Placebo, Electroencephalogram (EEG); Drug · Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: TBI (Traumatic Brain Injury), Concussion, Brain, Sport Injury, Anterior Pituitary Hyposecretion Syndrome, Hypopituitarism, Growth Hormone Deficiency
Interventions: Growth Hormone, Placebo; Biological · Other
Lead sponsor: Center for Neurological Studies; Other
Eligibility: 18 Years to 76 Years · Male only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Dearborn, Michigan

Conditions: Opioid Abuse, Benzodiazepine Abuse, Polysubstance Abuse
Interventions: Morphine, Alprazolam, Placebo; Drug
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Cystic Fibrosis
Interventions: LAU-7b, Placebo oral capsule; Drug
Lead sponsor: Laurent Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 27
States / cities: Long Beach, California • Los Angeles, California • Sacramento, California + 24 more

Conditions: Dementia Alzheimer's Type
Interventions: SAR110894, placebo (for SAR110894), Donepezil; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 55 Years and older
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 27
States / cities: Gilbert, Arizona • Phoenix, Arizona • Costa Mesa, California + 24 more

Conditions: Type2diabetes, Diabetic Kidney Disease
Interventions: Investigational Product - MIB 626, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 30 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infection, Inflammation, Cardiovascular Disease, HIV Infections
Interventions: raltegravir, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Obstructive Sleep Apnea
Interventions: AD036 Dose 1, AD036 Dose 2, AD036 Dose 3, Placebo; Drug
Lead sponsor: Apnimed; Industry
Eligibility: 25 Years to 70 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 12
States / cities: Glendale, Arizona • Little Rock, Arkansas • Redwood City, California + 9 more

Conditions: HIV Infections
Interventions: Patients elected to take licensed drugs. The vaccine was not provided for evaluation, multiple licensed drugs not randomized, multiple licensed antiretroviral drugs; not randomized, Intended vaccine not provided, Licensed drugs provided, but were not investigated; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose

Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions

Drug and Non-Drug Treatment Of Severe Migraine

Study of Duloxetine vs Placebo in Treatment of Binge Eating Disorder With Depression

Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants

Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement

Pilot E2 for Hypogonadal Women With CFBD

A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes

Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp

A Study of Viracept in HIV-Positive Women

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Without HIV

This is a Study to Determine the Antidepressant Effects of AZD6765

Dysphagia Following Anterior Cervical Spine Surgery; Single Dose Steroid vs Saline (DysDexVSSal)

The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial

Delirium Prevention With Ketamine in Ear, Nose, and Throat (ENT) Patients

Growth Hormone Replacement Therapy for Retried Professional Football Players

Opioid/Benzodiazepine Polydrug Abuse: Aim 3

Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults

Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

NAD Augmentation in Diabetes Kidney Disease

Effect of Raltegravir on Endothelial Function in HIV-Infected Patients

Trial of AD036 in Obstructive Sleep Apnea

Controlling Acute or Early HIV Infection With Antiretroviral Drugs, Without a Candidate Vaccine.As Reported Previously, the Candidate Vaccie Was Not Provided by the Maufacturer as Promised